AstraZeneca's Calquence Approved In China For Chronic Lymphocytic Leukaemia

(RTTNews) - China's National Medical Products Administration approved AstraZeneca plc.'s (AZN, AZN.L) Calquence or acalabrutinib for the treatment of adult patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma who have received at least one prior therapy. Calq https://www.nasdaq.com/articles/astrazenecas-calquence-approved-in-china-for-chronic-lymphocytic-leukaemia